Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lomustine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Alkylating agent

Related drugs:

‹

›

No biomarker	Brain Cancer	No biomarker	Brain Cancer	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1	lomustine Sensitive: A1 - Approval lomustine Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline cisplatin + vincristine + lomustine Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
No biomarker	Ependymoma	No biomarker	Ependymoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2
Chr del(1p)+ Chr del(19q)	Glioma	Chr del(1p)+ Chr del(19q)	Glioma	vincristine + lomustine + procarbazine hydrochloride Sensitive: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Sensitive : C3	vincristine + lomustine + procarbazine hydrochloride Sensitive: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Sensitive : C3
Chr del(1p)	Glioma	Chr del(1p)	Glioma	vincristine + lomustine + procarbazine hydrochloride Sensitive: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Sensitive : C3	vincristine + lomustine + procarbazine hydrochloride Sensitive: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Sensitive : C3
CDKN2A deletion	Glioma	CDKN2A deletion	Glioma	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3
ROR2 overexpression	Melanoma	ROR2 overexpression	Melanoma	lomustine Resistant: D – Preclinical lomustine Resistant : D	lomustine Resistant: D – Preclinical lomustine Resistant : D